Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis

Area of Science:

• Rheumatology
• Pharmacology
• Clinical Medicine

Background:

• Tofacitinib is the first Janus kinase (JAK) inhibitor approved for rheumatoid arthritis (RA).
• Extensive data exist on its efficacy and safety in various patient groups and treatment phases.

Purpose of the Study:

• To summarize clinical efficacy and safety data of tofacitinib in rheumatoid arthritis.
• To evaluate data across diverse demographics, treatment stages, and specific subpopulations.

Main Methods:

• Review of clinical trials, post hoc analyses, and real-world studies.
• Inclusion of data from the ORAL Surveillance post-marketing safety study.
• Analysis of safety in patient subpopulations, including older adults with cardiovascular risk factors.

Main Results:

• Tofacitinib shows efficacy in RA patients at various treatment stages and with different baseline characteristics (age, gender, race, BMI).
• Safety data are available for diverse subpopulations, informing risk-benefit assessments.
• The ORAL Surveillance study provides crucial safety insights for specific patient groups.

Conclusions:

• Tofacitinib efficacy and safety data support its use in varied RA patient populations.
• Evidence enables informed decision-making and personalized treatment strategies.
• Data facilitate better clinician-patient discussions for individualized care in RA management.